KHYAP
2021-09-24
🤞🏼🤞🏼
These 2 Nasdaq Small Caps Just Got Big Boosts
免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。
分享至
微信
复制链接
精彩评论
我们需要你的真知灼见来填补这片空白
打开APP，发表看法
APP内打开
发表看法
2
9
{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":861177980,"tweetId":"861177980","gmtCreate":1632476761540,"gmtModify":1632720085889,"author":{"id":3562150941808297,"idStr":"3562150941808297","authorId":3562150941808297,"authorIdStr":"3562150941808297","name":"KHYAP","avatar":"https://static.tigerbbs.com/134bef1736613cccadcb5091adcc32aa","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":3,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":26,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>🤞🏼🤞🏼</p></body></html>","htmlText":"<html><head></head><body><p>🤞🏼🤞🏼</p></body></html>","text":"🤞🏼🤞🏼","highlighted":1,"essential":1,"paper":1,"likeSize":9,"commentSize":2,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/861177980","repostId":1141045048,"repostType":4,"repost":{"id":"1141045048","kind":"news","pubTimestamp":1632476632,"share":"https://www.laohu8.com/m/news/1141045048?lang=&edition=full","pubTime":"2021-09-24 17:43","market":"us","language":"en","title":"These 2 Nasdaq Small Caps Just Got Big Boosts","url":"https://stock-news.laohu8.com/highlight/detail?id=1141045048","media":"Motley Fool","summary":"In a rising market, these companies looked especially impressive.\n\nKey Points\n\nThe Nasdaq made big g","content":"<blockquote>\n <b>In a rising market, these companies looked especially impressive.</b>\n</blockquote>\n<p><b>Key Points</b></p>\n<ul>\n <li>The Nasdaq made big gains on Thursday.</li>\n <li>Veritone rose on an extended agreement with CBS News.</li>\n <li>PAVmed announced it had filed IPO paperwork for a major subsidiary.</li>\n</ul>\n<p>Thursday was another great day for the stock market, although the <b>Nasdaq Composite</b> lagged behind some other major market benchmarks. Nevertheless, the Nasdaq managed to gain almost a full percentage point by 12:30 p.m. EDT, and it moved to within just a few percent of all-time record highs.</p>\n<p>Small-cap stocksdon't always get as much attention as their larger counterparts, but they often have the best growth prospects. On Thursday morning, shares of <b><a href=\"https://laohu8.com/S/VERI\">Veritone Inc.</a></b> and <b><a href=\"https://laohu8.com/S/PAVM\">PAVmed</a></b> were among the top performers on the Nasdaq. Below, we'll look more closely at the news that moved these stocks, with an eye toward trying to figure out whether they'll be able to sustain their upward momentum.</p>\n<p><b>A very valuable agreement for Veritone</b></p>\n<p>Shares of Veritone were higher by more than 13% on Thursday morning. The provider of enterprise artificial-intelligence software announced a major deal that could play a key role in driving growth in the years to come.</p>\n<p>Veritone has had a long relationship with the CBS News unit of<b>ViacomCBS</b>(NASDAQ:VIAC), spanning 11 years. It helps television producers, filmmakers, and other content creators take full advantage of news archive footage by using search and discovery functionality in its aiWARE platform. However, with the extended agreement announced today, Veritone and CBS News will boost access to the global creative community, allowing access not just to archival footage but also to breaking news content.</p>\n<p>The exclusive international agreement will cover the next three years. With millions of hours in its library of content, CBS News and Veritone see the deal having a substantial influence on creators seeking to tie their content to current and past news events.</p>\n<p>Veritone has made numerous effortsto foster its growth, including recent acquisitions to expand the functionality of its platform. Those efforts are now paying off in the CBS deal, and it'll be interesting to see how Veritone takes advantage of greater visibility as a result.</p>\n<p><b>Paving the way</b></p>\n<p>Elsewhere, shares of PAVmed soared 16%. The maker of medical devices plans to do an initial public offering for one of its subsidiaries, potentially offering shareholders a chance to benefit directly from its prospects.</p>\n<p>PAVmed is a majority owner of Lucid Diagnostics, which is responsible for what it says is the first and only commercial tools for widespread early detection of esophageal pre-cancer and cancer. Lucid also has a gastrointestinal health division that includes a different esophageal device for use in different indications.</p>\n<p>PAVmed's announcement revealed that Lucid has filed an S-1 registration statement with the Securities and Exchange Commission to go public. Lucid's ticker on the Nasdaq will be LUCD.</p>\n<p>After the spinoff, PAVmed will be left with its remaining businesses, including its Veris Health digital sensor and patient monitoring subsidiary. Other divisions include minimally invasive devices treating carpal tunnel syndrome and various other innovative medical devices.</p>\n<p>PAVmed has climbed substantially this year, with the key appointment of a well-known executive in the genetic diagnostics field helping to bolster the value of Lucid's business in particular. Investors will have a chance to choose whether they see more value in Lucid or in PAVmed's other businesses after the IPO is complete.</p>\n<p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>These 2 Nasdaq Small Caps Just Got Big Boosts</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nThese 2 Nasdaq Small Caps Just Got Big Boosts\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-24 17:43 GMT+8 <a href=https://www.fool.com/investing/2021/09/23/these-2-nasdaq-small-caps-just-got-big-boosts/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>In a rising market, these companies looked especially impressive.\n\nKey Points\n\nThe Nasdaq made big gains on Thursday.\nVeritone rose on an extended agreement with CBS News.\nPAVmed announced it had ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/09/23/these-2-nasdaq-small-caps-just-got-big-boosts/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PAVM":"PAVmed Inc.","VERI":"Veritone Inc."},"source_url":"https://www.fool.com/investing/2021/09/23/these-2-nasdaq-small-caps-just-got-big-boosts/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1141045048","content_text":"In a rising market, these companies looked especially impressive.\n\nKey Points\n\nThe Nasdaq made big gains on Thursday.\nVeritone rose on an extended agreement with CBS News.\nPAVmed announced it had filed IPO paperwork for a major subsidiary.\n\nThursday was another great day for the stock market, although the Nasdaq Composite lagged behind some other major market benchmarks. Nevertheless, the Nasdaq managed to gain almost a full percentage point by 12:30 p.m. EDT, and it moved to within just a few percent of all-time record highs.\nSmall-cap stocksdon't always get as much attention as their larger counterparts, but they often have the best growth prospects. On Thursday morning, shares of Veritone Inc. and PAVmed were among the top performers on the Nasdaq. Below, we'll look more closely at the news that moved these stocks, with an eye toward trying to figure out whether they'll be able to sustain their upward momentum.\nA very valuable agreement for Veritone\nShares of Veritone were higher by more than 13% on Thursday morning. The provider of enterprise artificial-intelligence software announced a major deal that could play a key role in driving growth in the years to come.\nVeritone has had a long relationship with the CBS News unit ofViacomCBS(NASDAQ:VIAC), spanning 11 years. It helps television producers, filmmakers, and other content creators take full advantage of news archive footage by using search and discovery functionality in its aiWARE platform. However, with the extended agreement announced today, Veritone and CBS News will boost access to the global creative community, allowing access not just to archival footage but also to breaking news content.\nThe exclusive international agreement will cover the next three years. With millions of hours in its library of content, CBS News and Veritone see the deal having a substantial influence on creators seeking to tie their content to current and past news events.\nVeritone has made numerous effortsto foster its growth, including recent acquisitions to expand the functionality of its platform. Those efforts are now paying off in the CBS deal, and it'll be interesting to see how Veritone takes advantage of greater visibility as a result.\nPaving the way\nElsewhere, shares of PAVmed soared 16%. The maker of medical devices plans to do an initial public offering for one of its subsidiaries, potentially offering shareholders a chance to benefit directly from its prospects.\nPAVmed is a majority owner of Lucid Diagnostics, which is responsible for what it says is the first and only commercial tools for widespread early detection of esophageal pre-cancer and cancer. Lucid also has a gastrointestinal health division that includes a different esophageal device for use in different indications.\nPAVmed's announcement revealed that Lucid has filed an S-1 registration statement with the Securities and Exchange Commission to go public. Lucid's ticker on the Nasdaq will be LUCD.\nAfter the spinoff, PAVmed will be left with its remaining businesses, including its Veris Health digital sensor and patient monitoring subsidiary. Other divisions include minimally invasive devices treating carpal tunnel syndrome and various other innovative medical devices.\nPAVmed has climbed substantially this year, with the key appointment of a well-known executive in the genetic diagnostics field helping to bolster the value of Lucid's business in particular. Investors will have a chance to choose whether they see more value in Lucid or in PAVmed's other businesses after the IPO is complete.","news_type":1},"isVote":1,"tweetType":1,"viewCount":163,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":8,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/861177980"}
精彩评论